Indigenous Australian Status May Be a Predictor of Mortality After ACS
Aboriginal and Torres Strait Islander status may predict death in individuals with acute coronary syndrome.
Acute Coronary Syndrome
Incidence of Muscle Complaints Not Found to Increase When Adding Ezetimibe to Simvastatin After ACS
The addition of the ezetimibe to simvastatin in patients with a recent acute coronary syndrome was not found to be associated with an increased incidence of patient-reported muscle complaints.
Improving Outcomes of Early Myocardial Infarction Rule-Out in the ED
In the early rule-out of myocardial infarction, outcomes may be improved by accounting for the patient’s out-of-hospital experience, improving reassurance communication, and discussing future goals for cardiovascular health.
Impaired Renal Function Found to Affect Long-Term Prognosis After PCI
Impaired renal function was found to have negative long-term effects in individuals with acute coronary syndrome after percutaneous coronary intervention.
Identification of Factors Associated With Contrast-Induced Nephropathy After PCI
Several factors were found to be associated with the development of contrast-induced nephropathy after percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome.
Elevated Cardiovascular Disease Risk in Patients With Inflammatory Arthritis
Researchers assessed the prevalence and incidence rate of cardiovascular morbidity in patients with inflammatory arthritis and determined whether the coexistence of multiple autoimmune disorders was associated with increased risk for cardiovascular disease.
Examining Challenges Associated With the Management of ACS in Rural Areas
Although mortality rates associated with cardiovascular disease have decreased significantly in high-income countries in recent decades, substantial challenges related to CVD treatment and outcomes persist in rural areas.
Biomarkers to Assess Risk Level for Expanded HF in T2DM After ACS
A set of biomarkers and clinical variables was found to facilitate the assessment of the risk level for expanded heart failure outcomes in patients with type 2 diabetes mellitus and a recent history of acute coronary syndrome.
Apabetalone Gets Breakthrough Therapy Designation for MACE Prevention
The FDA has granted Breakthrough Therapy designation to apabetalone in combination with standard of care therapy for the secondary prevention of MACE in patients with T2Dm and recent ACS.
Low Diagnostic Accuracy of ECG Criteria for ACS in ED Patients With Chest Pain
The electrocardiogram criteria for acute coronary syndrome were found to have very low diagnostic accuracy in patients presenting to the emergency department with chest pain.
